A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy

详细信息    查看全文

• 作者：Na Liu ; Yanan Tan ; Yingwen Hu ; Tingting Meng ; Lijuan Wen ; Jingwen Liu ; Bolin Cheng ; Hong Yuan ; Xuan Huang ; Fuqiang Hu
• 刊名：ACS Applied Materials & Interfaces
• 出版年：2016
• 出版时间：December 7, 2016
• 年：2016
• 卷：8
• 期：48
• 页码：33148-33156
• 全文大小：555K
• ISSN：1944-8252

文摘

Redox-responsive nanomaterials applied in drug delivery systems (DDS) have attracted an increasing attention in pharmaceutical research as a carrier for antitumor therapy. However, there would be unwanted drug release from a redox-responsive DDS with no selection at nontarget sites, leading to undesirable toxicities in normal tissues and cells. Here, an A54 peptide modified and PEGylated reduction cleavable glucolipid conjugate (A54-PEG-CSO-ss-SA, abbreviated to APC_ssA) was designed for intracellular delivery of doxorubicin (DOX). The synthesized APC_ssA could be assembled via micellization self-assembly in aqueous water above the critical micelle concentration (54.9 μg/mL) and exhibited a high drug encapsulation efficiency (77.92%). The APC_ssA micelles showed an enhanced redox sensitivity in that the disulfide bond could be degraded quickly and the drug would be released from micelles in 10 mM levels of glutathione (GSH). The cellular uptake studies highlighted the affinity of APC_ssA micelles toward the hepatoma cells (BEL-7402) compared to that toward HepG2 cells. In contrast with the nonresponsive conjugate, the drug was released from APC_ssA micelles more quickly in 10 mM level of GSH concentration (tumor cells). Moreover, the DOX-loaded APC_ssA micelles displayed an increased cytotoxicity which was 1.6- to 2.0-fold that of unmodified and nonresponsive micelles. In vivo, the APC_ssA micelles had stronger distribution to liver and hepatoma tissue and prolonged the circulation and retention time, while the drug release only occurred in the tumor tissue. The APC_ssA/DOX showed the tumor inhibition rate equal to that of commercial doxorubicin hydrochloric without negative consequence. This study suggested that the APC_ssA/DOX showed promising potential to treat the tumor for its special tumor targeting, selective intracellular drug release, enhanced antitumor activity, and reduced toxicity on normal tissues.